All Stories

  1. Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026
  2. New regimens BPaL/BPaLM for DR-TB treatment not only saves lives, but also saves cost
  3. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?